Details
| Stereochemistry | RACEMIC |
| Molecular Formula | 3C15H13O3.Al |
| Molecular Weight | 750.7673 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Al+3].CC(C([O-])=O)C1=CC(OC2=CC=CC=C2)=CC=C1.CC(C([O-])=O)C3=CC(OC4=CC=CC=C4)=CC=C3.CC(C([O-])=O)C5=CC(OC6=CC=CC=C6)=CC=C5
InChI
InChIKey=MPLRWVOHWPDIJH-UHFFFAOYSA-K
InChI=1S/3C15H14O3.Al/c3*1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13;/h3*2-11H,1H3,(H,16,17);/q;;;+3/p-3
DescriptionSources: http://www.drugbank.ca/drugs/DB00573Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/fenoprofen.html
Sources: http://www.drugbank.ca/drugs/DB00573
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/fenoprofen.html
Fenoprofen is a propionic acid derivative with analgesic, antiinflammatory and antipyretic properties. Fenoprofen inhibits prostaglandin synthesis by decreasing the enzyme needed for biosynthesis. In patients with rheumatoid arthritis, the anti-inflammatory action of fenoprofen has been evidenced by relief of pain, increase in grip strength, and reductions in joint swelling, duration of morning stiffness, and disease activity (as assessed by both the investigator and the patient). In patients with osteoarthritis, the anti-inflammatory and analgesic effects of fenoprofen have been demonstrated by reduction in tenderness as a response to pressure and reductions in night pain, stiffness, swelling, and overall disease activity (as assessed by both the patient and the investigator). These effects have also been demonstrated by relief of pain with motion and at rest and increased range of motion in involved joints. In patients with rheumatoid arthritis and osteoarthritis, clinical studies have shown fenoprofen to be comparable to aspirin in controlling the aforementioned measures of disease activity, but mild gastrointestinal reactions (nausea, dyspepsia) and tinnitus occurred less frequently in patients treated with fenoprofen than in aspirin-treated patients. It is not known whether fenoprofen causes less peptic ulceration than does aspirin. In patients with pain, the analgesic action of fenoprofen has produced a reduction in pain intensity, an increase in pain relief, improvement in total analgesia scores, and a sustained analgesic effect. Indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Also for the relief of mild to moderate pain.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL230 Sources: http://www.drugbank.ca/drugs/DB00573 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
|||
| Primary | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
|||
| Primary | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
28.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
105.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
Disc. AE: Reaction gastrointestinal, Reaction skin... Other AEs: Dyspepsia, Nausea... AEs leading to discontinuation/dose reduction: Reaction gastrointestinal (2%) Other AEs:Reaction skin (1%) Cardiovascular disorder (NOS) (0.5%) Dyspepsia (10%) Sources: Nausea (7.7%) Constipation (7%) Vomiting (2.6%) Abdominal pain (2%) Diarrhea (1.8%) Headache (8.7%) Somnolence (8.5%) Dizziness (6.5%) Tremor (2.2%) Confusion (1.4%) Sweating increased (4.6%) Pruritus (4.2%) Rash (3.7%) Tinnitus (4.5%) Blurred vision (2.2%) Hearing decreased (1.6%) Palpitations (2.5%) Nervousness (5.7%) Asthenia (5.4%) Peripheral edema (5%) Dyspnea (2.8%) Fatigue (1.7%) Upper respiratory infection (1.5%) Nasopharyngitis (1.2%) Gastritis (<1%) Ulcer peptic with perforation (<1%) Ulcer peptic with perforation (<1%) Gastrointestinal hemorrhage (<1%) Anorexia (<1%) Flatulence (<1%) Dry mouth (<1%) Blood in stool (<1%) Alkaline phosphatase increased (<1%) LDH increased (<1%) SGOT increased (<1%) Jaundice (<1%) Cholestatic hepatitis (<1%) Buccal mucosa aphthous ulceration (<1%) Taste metallic (<1%) Pancreatitis (<1%) Atrial fibrillation (<1%) Pulmonary edema (<1%) Electrocardiogram change (<1%) Supraventricular tachycardia (<1%) Renal failure (<1%) Dysuria (<1%) Cystitis (<1%) Hematuria (<1%) Oliguria (<1%) Azotemia (<1%) Anuria (<1%) Nephritis interstitial (<1%) Nephrosis (<1%) Acute papillary necrosis (<1%) Angioedema (<1%) Purpura (<1%) Bruising (<1%) Hemorrhage (<1%) Thrombocytopenia (<1%) Hemolytic anemia (<1%) Aplastic anemia (<1%) Agranulocytosis (<1%) Pancytopenia (<1%) Depression (<1%) Disorientation (<1%) Seizures (<1%) Trigeminal neuralgia (<1%) Burning tongue (<1%) Diplopia (<1%) Optic neuritis (<1%) Exfoliative dermatitis (<1%) Toxic epidermal necrolysis (<1%) Stevens-Johnson syndrome (<1%) Alopecia (<1%) Anaphylaxis (<1%) Urticaria (<1%) Malaise (<1%) Insomnia (<1%) Tachycardia (<1%) Personality change (<1%) Lymphadenopathy (<1%) Mastodynia (<1%) Fever (<1%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cardiovascular disorder (NOS) | 0.5% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Reaction skin | 1% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nasopharyngitis | 1.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Confusion | 1.4% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Upper respiratory infection | 1.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Hearing decreased | 1.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Fatigue | 1.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Diarrhea | 1.8% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dyspepsia | 10% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Abdominal pain | 2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Reaction gastrointestinal | 2% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Blurred vision | 2.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Tremor | 2.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Palpitations | 2.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Vomiting | 2.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dyspnea | 2.8% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Rash | 3.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Pruritus | 4.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Tinnitus | 4.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Sweating increased | 4.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Peripheral edema | 5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Asthenia | 5.4% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nervousness | 5.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dizziness | 6.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Constipation | 7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nausea | 7.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Somnolence | 8.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Headache | 8.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Acute papillary necrosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Agranulocytosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Alkaline phosphatase increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Alopecia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Anaphylaxis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Angioedema | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Anorexia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Anuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Aplastic anemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Atrial fibrillation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Azotemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Blood in stool | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Bruising | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Buccal mucosa aphthous ulceration | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Burning tongue | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Cholestatic hepatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Cystitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Depression | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Diplopia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Disorientation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dry mouth | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dysuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Electrocardiogram change | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Exfoliative dermatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Fever | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Flatulence | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Gastritis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Gastrointestinal hemorrhage | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Hematuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Hemolytic anemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Hemorrhage | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Insomnia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Jaundice | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| LDH increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Lymphadenopathy | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Malaise | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Mastodynia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nephritis interstitial | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nephrosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Oliguria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Optic neuritis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Pancreatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Pancytopenia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Personality change | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Pulmonary edema | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Purpura | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Renal failure | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| SGOT increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Seizures | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Stevens-Johnson syndrome | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Supraventricular tachycardia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Tachycardia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Taste metallic | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Thrombocytopenia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Toxic epidermal necrolysis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Trigeminal neuralgia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Ulcer peptic with perforation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Ulcer peptic with perforation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Urticaria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. | 2001 |
|
| Enantioselective inhibition of the binding of rac-profens to human serum albumin induced by lithocholate. | 2001 Jul |
|
| Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation. | 2001 May-Jun |
|
| [Chiral separation by capillary electrochromatography on stationary phase adsorbed with protein]. | 2001 Sep |
|
| Analysis of acidic drugs in the effluents of sewage treatment plants using liquid chromatography-electrospray ionization tandem mass spectrometry. | 2002 Apr 5 |
|
| Capillary electrochromatographic separation of non-steroidal anti-inflammatory drugs with a histidine bonded phase. | 2002 Dec 27 |
|
| Macromolecular prodrugs: X. Kinetics of fenoprofen release from PHEA-fenoprofen conjugate. | 2002 Jul 25 |
|
| Prediction of selectivity for enantiomeric separations of uncharged compounds by capillary electrophoresis involving dual cyclodextrin systems. | 2002 Mar 1 |
|
| Renal papillary necrosis. | 2002 Nov-Dec |
|
| Quadrupole time-of-flight versus triple-quadrupole mass spectrometry for the determination of non-steroidal antiinflammatory drugs in surface water by liquid chromatography/tandem mass spectrometry. | 2003 |
|
| Determination of acidic pharmaceuticals, antibiotics and ivermectin in river sediment using liquid chromatography-tandem mass spectrometry. | 2003 Dec 22 |
|
| Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. | 2003 Jun 2 |
|
| Capillary electrophoresis with laser induced-fluorescence detection of profens derivatized with the water-soluble fluorogenic reagent 4-N-(4-N'-aminoethyl)piperazino-7-nitro-2,1,3-benzoxadiazole. | 2003 Sep 5 |
|
| Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. | 2004 Aug 2 |
|
| Optimization of sample stacking for the simultaneous determination of nonsteroidal anti-inflammatory drugs with a wall-coated histidine capillary column. | 2004 Feb |
|
| Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. | 2004 Jul 2 |
|
| Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen. | 2004 Nov |
|
| Cationic vesicles as chiral selector for enantioseparations of nonsteroidal antiinflammatory drugs by micellar electrokinetic chromatography. | 2004 Sep 3 |
|
| Using terahertz pulsed spectroscopy to quantify pharmaceutical polymorphism and crystallinity. | 2005 Apr |
|
| Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. | 2005 Jan 25 |
|
| Synthesis of fenoprofen and gemfibrozil styrene-maleic acid copolymer conjugates. | 2005 Jun |
|
| Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. | 2005 Nov |
|
| Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. | 2005 Nov 29 |
|
| The inflammatory process of gout and its treatment. | 2006 |
|
| Different sample stacking strategies to analyse some nonsteroidal anti-inflammatory drugs by micellar electrokinetic capillary chromatography in mineral waters. | 2006 Jun 9 |
|
| The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. | 2007 Apr 1 |
|
| Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. | 2007 Dec |
|
| A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives. | 2007 Dec 26 |
|
| Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. | 2007 Jan |
|
| A peripatetic pediatrician's journey into pediatric rheumatology: Part II. | 2007 Jun 21 |
|
| Enantioseparation by CE with vancomycin as chiral selector: Improving the separation performance by dynamic coating of the capillary with poly(dimethylacrylamide). | 2007 Mar |
|
| Stereoselective disposition of fenoprofen in plasma and synovial fluid of patients with rheumatoid arthritis. | 2007 May 5 |
|
| Removal of selected pharmaceuticals by chlorination, coagulation-sedimentation and powdered activated carbon treatment. | 2008 |
|
| Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. | 2008 |
|
| Chiral separation of fluvastatin enantiomers by capillary electrophoresis. | 2008 Aug |
|
| Using subcritical/supercritical fluid chromatography to separate acidic, basic, and neutral compounds over an ionic liquid-functionalized stationary phase. | 2009 Apr 17 |
|
| Synthesis of dehydroabietic acid-modified chitosan and its drug release behavior. | 2009 Jan 5 |
|
| Antioxidant activity of NSAID hydroxamic acids. | 2009 Jun |
|
| The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. | 2010 |
|
| Rapid simultaneous determination of four non-steroidal anti-inflammatory drugs by means of derivative nonlinear variable-angle synchronous fluorescence spectrometry. | 2010 Aug |
|
| Cyclooxygenase Inhibitors, Aspirin and Ibuprofen, Inhibit MHC-restricted Antigen Presentation in Dendritic Cells. | 2010 Jun |
|
| Use of a robust dehydrogenase from an archael hyperthermophile in asymmetric catalysis-dynamic reductive kinetic resolution entry into (S)-profens. | 2010 May 5 |
|
| Primaquine-NSAID twin drugs: Synthesis, radical scavenging, antioxidant and Fe2+ chelating activity. | 2010 Sep |
|
| Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping. | 2010 Sep 16 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
126961359
Created by
admin on Sat Dec 16 10:47:45 GMT 2023 , Edited by admin on Sat Dec 16 10:47:45 GMT 2023
|
PRIMARY | |||
|
R56740U8WB
Created by
admin on Sat Dec 16 10:47:45 GMT 2023 , Edited by admin on Sat Dec 16 10:47:45 GMT 2023
|
PRIMARY | |||
|
101623-39-6
Created by
admin on Sat Dec 16 10:47:45 GMT 2023 , Edited by admin on Sat Dec 16 10:47:45 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
